Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been given an average rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the […]
HC Wainwright reissued their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q1 2024 earnings at ($0.88) EPS, Q2 2024 earnings at ($0.92) […]
Acrivon Therapeutics (NASDAQ: ) just reported results for the fourth quarter of 2023. InvestorPlace Earnings is a project that leverages data from TradeSmith…
Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.